These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 31596642)

  • 1. Manufacturing process optimization of ADMA Biologics' intravenous immunoglobulin products, BIVIGAM
    Wasserman RL; Garcia D; Greener BN; Kestenberg K; Pinkert A; Mond J; Grossman A
    Immunotherapy; 2019 Nov; 11(16):1423-1433. PubMed ID: 31596642
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A new intravenous immunoglobulin (BIVIGAM®) for primary humoral immunodeficiency.
    Wasserman RL
    Expert Rev Clin Immunol; 2014 Mar; 10(3):325-37. PubMed ID: 24527947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using intravenous immunoglobulin (IVIG) to treat patients with primary immune deficiency disease.
    Bonagura VR
    J Clin Immunol; 2013 Jan; 33 Suppl 2():S90-4. PubMed ID: 23271459
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Individualized immunoglobulin treatment in pediatric patients with primary humoral immunodeficiency disease.
    Patel NC
    Pediatr Allergy Immunol; 2018 Sep; 29(6):583-588. PubMed ID: 29744952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on the use of immunoglobulin in human disease: A review of evidence.
    Perez EE; Orange JS; Bonilla F; Chinen J; Chinn IK; Dorsey M; El-Gamal Y; Harville TO; Hossny E; Mazer B; Nelson R; Secord E; Jordan SC; Stiehm ER; Vo AA; Ballow M
    J Allergy Clin Immunol; 2017 Mar; 139(3S):S1-S46. PubMed ID: 28041678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Idiotype-specific intravenous immunoglobulin for therapy of immunoglobulin kappa free light chain deficiency.
    Stanciu AE; Popescu M; Gheorghe DC
    Hum Vaccin Immunother; 2019; 15(5):1123-1125. PubMed ID: 30676854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of the manufacturing process on the anti-A isoagglutinin titers in intravenous immunoglobulin products.
    Romberg V; Hoefferer L; El Menyawi I
    Transfusion; 2015 Jul; 55 Suppl 2():S105-9. PubMed ID: 26174887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of routes of IgG administration.
    Torgerson TR
    J Clin Immunol; 2013 Jan; 33 Suppl 2():S87-9. PubMed ID: 23229780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of intravenous immunoglobulin (IVIG) therapy in adults.
    Herrod HG
    Allergy Proc; 1994; 15(6):309-12. PubMed ID: 7721079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A newer immunoglobulin intravenous (IGIV) - Gammagard liquid 10%: evaluation of efficacy, safety, tolerability and impact on patient care.
    Shah SR
    Expert Opin Biol Ther; 2008 Jun; 8(6):799-804. PubMed ID: 18476791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A multicentre, prospective, non-randomized, sequential, open-label trial to demonstrate the bioequivalence between intravenous immunoglobulin new generation (IGNG) and standard IV immunoglobulin (IVIG) in adult patients with primary immunodeficiency (PID).
    Viallard JF; Brion JP; Malphettes M; Durieu I; Gardembas M; Schleinitz N; Hoarau C; Lazaro E; Puget S
    Rev Med Interne; 2017 Sep; 38(9):578-584. PubMed ID: 28683953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Technology of immunoglobulin production. I. Technological aspects of purification].
    Volkov GL
    Ukr Biokhim Zh (1999); 2006; 78(3):88-98. PubMed ID: 17100315
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune globulin (human) 10 % liquid: a review of its use in primary immunodeficiency disorders.
    McCormack PL
    BioDrugs; 2013 Aug; 27(4):393-400. PubMed ID: 23703447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases.
    Wasserman RL
    Immunotherapy; 2017 Sep; 9(12):1035-1050. PubMed ID: 28871852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoglobulin replacement therapy in primary antibody deficiency diseases--maximizing success.
    Durandy A; Wahn V; Petteway S; Gelfand EW
    Int Arch Allergy Immunol; 2005 Mar; 136(3):217-29. PubMed ID: 15713984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Should therapeutic immunoglobulin be considered a generic product? An evidence-based approach.
    Misbah SA
    J Allergy Clin Immunol Pract; 2013; 1(6):567-72. PubMed ID: 24565702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Purification of intravenous immunoglobulin G from human plasma--aspects of yield and virus safety.
    Buchacher A; Iberer G
    Biotechnol J; 2006 Feb; 1(2):148-63. PubMed ID: 16892245
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Human intravenous immunoglobulin preparation and virus inactivation by pasteurization and solvent detergent treatment.
    Chang CE; Eo HG; Lee YS; Chung SK; Shin JS; Lah YK; Park CW; Jung JT; Huh JW; Lee SM
    Prep Biochem Biotechnol; 2000 Aug; 30(3):177-97. PubMed ID: 10919559
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunoglobulins and their use in children.
    Łaguna P; Gołębiowska-Staroszczyk S; Trzaska M; Grabarczyk M; Matysiak M
    Adv Clin Exp Med; 2015; 24(1):153-9. PubMed ID: 25923100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid infusions of human normal immunoglobulin 50g/l are safe and well tolerated in immunodeficiencies and immune thrombocytopenia.
    Spadaro G; Vultaggio A; Alberto Bosi A; Reichert D; Janssen J; Lamacchia D; Nappi L; Pecoraro A; Milito C; Ferraro A; Matucci A; Bacchiarri F; Carrai V; Hibbeler A; Speckman E; Guarnieri C; Bongiovanni S; Quinti I
    Int Immunopharmacol; 2017 Mar; 44():38-42. PubMed ID: 28073042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.